Literature DB >> 2473473

Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia.

M E Smith1, S G Marsh, J G Bodmer, K Gelsthorpe, W F Bodmer.   

Abstract

The expression of HLA-A,B,C antigens and lymphocyte function-associated antigen 3 in human colorectal adenomas and adenocarcinomas was studied by immunohistochemistry. None of 10 adenomas and only 1 of 30 carcinomas had lost expression of all HLA-A,B,C molecules. On the other hand, focal loss of an HLA-B product was seen in 2 of the adenomas, and complete losses of tumor cell HLA-A2 (in 7 of 13 cases), HLA-Bw4 (in 4 of 13 cases), and HLA-A3 (in 1 of 6 cases) were seen in the carcinomas. No complete losses of HLA-A1 (in 6 cases) or HLA-Bw6 (in 22 cases) occurred in the carcinomas. In addition, 1 of 20 adenocarcinomas totally lacked lymphocyte function-associated antigen 3. Because a loss of tumor cell HLA-A,B,C antigen or lymphocyte function-associated antigen 3 could be selected for through an advantage in escape from cytotoxic T-lymphocyte attack, our results suggest that immunoselection may be a more important mechanism in tumor progression than has previously been assumed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2473473      PMCID: PMC297662          DOI: 10.1073/pnas.86.14.5557

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  Monoclonal antibodies for analysis of the HLA system.

Authors:  F M Brodsky; P Parham; C J Barnstable; M J Crumpton; W F Bodmer
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

2.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

3.  A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17.

Authors:  A J McMichael; P Parham; N Rust; F Brodsky
Journal:  Hum Immunol       Date:  1980-09       Impact factor: 2.850

Review 4.  Variation in MHC antigenic profiles of tumor cells and its biological effects.

Authors:  H Festenstein; W Schmidt
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

5.  The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin.

Authors:  B Arce-Gomez; E A Jones; C J Barnstable; E Solomon; W F Bodmer
Journal:  Tissue Antigens       Date:  1978-02

6.  Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens.

Authors:  F M Brodsky; W F Bodmer; P Parham
Journal:  Eur J Immunol       Date:  1979-07       Impact factor: 5.532

7.  Cell-free translation of the mRNAs for the heavy and light chains of HLA-A and HLA-B antigens.

Authors:  H L Ploegh; L E Cannon; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

8.  A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1.

Authors:  R Rothlein; M L Dustin; S D Marlin; T A Springer
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

9.  Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines.

Authors:  P J Travers; J L Arklie; J Trowsdale; R A Patillo; W F Bodmer
Journal:  Natl Cancer Inst Monogr       Date:  1982

10.  HLA B37 determines an influenza A virus nucleoprotein epitope recognized by cytotoxic T lymphocytes.

Authors:  A J McMichael; F M Gotch; J Rothbard
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more
  27 in total

1.  CD antigens as promising tools for the functional analysis of solid tumours.

Authors:  P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Sporadic loss of leucocyte-function-associated antigen-3 (LFA-3) in colorectal carcinomas.

Authors:  K Koretz; P Schlag; P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.

Authors:  Ainhoa Arina; Theodore Karrison; Eva Galka; Karin Schreiber; Ralph R Weichselbaum; Hans Schreiber
Journal:  Cancer Immunol Res       Date:  2017-01-11       Impact factor: 11.151

Review 4.  Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease.

Authors:  J P Johnson
Journal:  Cancer Metastasis Rev       Date:  1991-05       Impact factor: 9.264

5.  Sequence polymorphism in the HLA-B promoter region.

Authors:  Z Yao; A Volgger; S Scholz; E D Albert
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

6.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

7.  HLA antigen expression in enteropathy associated T cell lymphoma.

Authors:  M Ashton-Key; N Singh; L X Pan; M E Smith
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

8.  Highly lytic CD8+, alpha beta T-cell receptor cytotoxic T cells with major histocompatibility complex (MHC) class I antigen-directed cytotoxicity in beta 2-microglobulin, MHC class I-deficient mice.

Authors:  S Apasov; M Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

9.  Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer.

Authors:  L Kaklamanis; A Townsend; I A Doussis-Anagnostopoulou; N Mortensen; A L Harris; K C Gatter
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

10.  Expression of beta 2-microglobulin by human benign and malignant mesenchymal and neurogenic tumours.

Authors:  B L Petersen; O Braendstrup
Journal:  Int J Exp Pathol       Date:  1993-08       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.